Retina (Philadelphia, Pa.) · 2025
Secondary Enucleation in Retinoblastoma: Clinical features predictive of high-risk histopathology Features in 295 Eyes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vempuluru Vijitha S, Bakal Komal, Agarwal Purva, Kaur Gurkiran, Kaliki Swathi
Аннотация
PURPOSE: To report the incidence of high-risk histopathology features (HRHF) in secondarily enucleated eyes of retinoblastoma (RB) and to identify its clinical predictors.
METHODS: Retrospective study of 295 secondarily enucleated eyes of 289 RB patients.
RESULTS: The mean age at presentation of RB was 23 months (median, 18 months, range, <1 to 144 months). Indications for secondary enucleation included persistent/recurrent/progressive active tumor (n=246, 83%) or loss of fundus view (n=49, 17%). HRHFs were noted in 49 (17%) eyes including iris infiltration (n=12, 4%), ciliary body infiltration (n=12, 4%), massive choroidal invasion (n=22, 7%), postlaminar (n=3, 1%), optic nerve transected margin involvement (n=2, <1%), combination of optic nerve and choroidal involvement (n=4, 1%), and scleral infiltration (n=9, 3%). After a mean follow-up of 35 months (median, 26 months; range, 1 to 161 months) from secondary enucleation, systemic metastasis and death occurred in 2 (<1%) patients. The predictors of HRHF in cases of secondary enucleation included age >36 months at the time of enucleation (p<0.001), an interval of >12 months from first treatment to enucleation (p<0.001), an interval of >1 month from last treatment to enucleation (p<0.001), and persistent/recurrent/progressive tumor despite >9 cycles of systemic chemotherapy before enucleation (p<0.001).
CONCLUSION: While aiming for global salvage in the management of retinoblastoma, caution should be exercised for patients >36 months of age, with a treatment duration of >12 months and a requirement of >9 cycles of systemic chemotherapy. When secondary enucleation is planned, care providers should be warned against deferring it beyond 1 month.
METHODS: Retrospective study of 295 secondarily enucleated eyes of 289 RB patients.
RESULTS: The mean age at presentation of RB was 23 months (median, 18 months, range, <1 to 144 months). Indications for secondary enucleation included persistent/recurrent/progressive active tumor (n=246, 83%) or loss of fundus view (n=49, 17%). HRHFs were noted in 49 (17%) eyes including iris infiltration (n=12, 4%), ciliary body infiltration (n=12, 4%), massive choroidal invasion (n=22, 7%), postlaminar (n=3, 1%), optic nerve transected margin involvement (n=2, <1%), combination of optic nerve and choroidal involvement (n=4, 1%), and scleral infiltration (n=9, 3%). After a mean follow-up of 35 months (median, 26 months; range, 1 to 161 months) from secondary enucleation, systemic metastasis and death occurred in 2 (<1%) patients. The predictors of HRHF in cases of secondary enucleation included age >36 months at the time of enucleation (p<0.001), an interval of >12 months from first treatment to enucleation (p<0.001), an interval of >1 month from last treatment to enucleation (p<0.001), and persistent/recurrent/progressive tumor despite >9 cycles of systemic chemotherapy before enucleation (p<0.001).
CONCLUSION: While aiming for global salvage in the management of retinoblastoma, caution should be exercised for patients >36 months of age, with a treatment duration of >12 months and a requirement of >9 cycles of systemic chemotherapy. When secondary enucleation is planned, care providers should be warned against deferring it beyond 1 month.